ASH News Daily 2012 - Saturday, December 8, 2012 - (Page A-7)

T:21.5” BECAUSE THE CONSEQUENCES CAN BE DEVASTATING1-4 70% aHUS of aHUS patients (with the most common mutation*) die, require dialysis, or have permanent renal damage within 1 year4 *CFH mutations = most common mutations4 • In aHUS, uncontrolled complement activation leads to systemic thrombotic microangiopathy (TMA)4,10-14 • 33% to 40% of all patients die or progress to end stage renal disease with the fi rst clinical manifestation4,10 • Plasma exchange/infusion (PE/PI) does not address chronic, uncontrolled complement activation, the underlying cause of TMA in aHUS10,13,15-20 • Differential diagnosis of aHUS is warranted9 aHUS = atypical hemolytic uremic syndrome Visit Alexion booth #2513 at ASH December 8-11, Georgia World Congress Center, Atlanta, GA, for more information and to pick up a videobook and USB key containing further details about PNH and aHUS. For more information about PNH and aHUS, visit www.PNHSource.com and www.aHUSSource.com F:10.75” © 2012, Alexion Pharmaceuticals, Inc. All rights reserved. SOL-1405 11/13/12 3:42 PM

Table of Contents for the Digital Edition of ASH News Daily 2012 - Saturday, December 8, 2012

ASH News Daily 2012 - Saturday, December 8, 2012

https://www.nxtbookmedia.com